Clinical Trials Directory

Trials / Completed

CompletedNCT00205257

Prediction of Acute Rejection in Renal Transplant

Prediction of Acute Graft Rejection by Examining Urine Chemokines in Patients With Kidney Transplant

Status
Completed
Phase
Study type
Observational
Enrollment
Sponsor
University of Wisconsin, Madison · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Acute rejection is still a major risk factor affecting the prognosis of kidney transplant patients. Alloreactive cells of the recipient infiltrate the kidney graft and cause inflammatory reaction which damages the graft structure and function. Conventional diagnosis of acute rejection is based on clinical symptoms and kidney biopsy examination. The clinical symptoms are a result of the kidney damage, which occurs days after the initiation of the rejection reaction. Kidney biopsy is an invasive and expensive procedure. It has been wished to have new parameters that can replace/supplement the conventional procedures. Chemokines are small molecules that attract inflammatory cells. Changes of chemokine levels in the urine may correlate with the immune status in the kidney. A systematic study to evaluate the chemokine levels in urine and correlation with the kidney biopsy pathology will answer the question whether monitoring of urinary chemokines would be useful in predicting graft rejection/damage.

Conditions

Timeline

Start date
2001-09-01
Primary completion
2007-02-01
Completion
2007-02-01
First posted
2005-09-20
Last updated
2015-10-05

Source: ClinicalTrials.gov record NCT00205257. Inclusion in this directory is not an endorsement.

Prediction of Acute Rejection in Renal Transplant (NCT00205257) · Clinical Trials Directory